Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large datasets by Grarup, Niels et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Genetic architecture of vitamin B12 and folate levels uncovered applying deeply
sequenced large datasets
Grarup, Niels; Sulem, Patrick; Sandholt, Camilla H; Thorleifsson, Gudmar; Ahluwalia, Tarun
Veer Singh; Steinthorsdottir, Valgerdur; Bjarnason, Helgi; Gudbjartsson, Daniel F;
Magnusson, Olafur T; Sparsø, Thomas; Albrechtsen, Anders; Kong, Augustine; Masson,
Gisli; Tian, Geng; Cao, Hongzhi; Nie, Chao; Kristiansen, Karsten; Husemoen, Lise Lotte;
Thuesen, Betina; Li, Yingrui; Nielsen, Rasmus; Linneberg, Allan; Olafsson, Isleifur;
Eyjolfsson, Gudmundur I; Jørgensen, Torben; Wang, Jun; Hansen, Torben; Thorsteinsdottir,
Unnur; Stefánsson, Kari; Pedersen, Oluf Borbye
Published in:
P L o S Genetics
DOI:
10.1371/journal.pgen.1003530
Publication date:
2013
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Grarup, N., Sulem, P., Sandholt, C. H., Thorleifsson, G., Ahluwalia, T. V. S., Steinthorsdottir, V., ... Pedersen, O.
B. (2013). Genetic architecture of vitamin B12 and folate levels uncovered applying deeply sequenced large
datasets. P L o S Genetics, 9(6), [e1003530]. https://doi.org/10.1371/journal.pgen.1003530
Download date: 02. Feb. 2020
Genetic Architecture of Vitamin B12 and Folate Levels
Uncovered Applying Deeply Sequenced Large Datasets
Niels Grarup1., Patrick Sulem2., Camilla H. Sandholt1., Gudmar Thorleifsson2, Tarunveer S. Ahluwalia1,
Valgerdur Steinthorsdottir2, Helgi Bjarnason2, Daniel F. Gudbjartsson2, Olafur T. Magnusson2,
Thomas Sparsø1, Anders Albrechtsen3, Augustine Kong2, Gisli Masson2, Geng Tian4, Hongzhi Cao4,
Chao Nie4, Karsten Kristiansen5, Lise Lotte Husemoen6, Betina Thuesen6, Yingrui Li4, Rasmus Nielsen3,7,8,
Allan Linneberg6, Isleifur Olafsson9, Gudmundur I. Eyjolfsson10, Torben Jørgensen6,11,12, Jun Wang1,4,5,
Torben Hansen1,13, Unnur Thorsteinsdottir2,14, Kari Stefa´nsson2,14*, Oluf Pedersen1,15,16,17*
1 The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark,
2 deCODE Genetics, Reykjavik, Iceland, 3Centre of Bioinformatics, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, 4 BGI-Shenzhen, Shenzhen,
China, 5Department of Biology, Faculty of Science, University of Copenhagen, Copenhagen, Denmark, 6 Research Centre for Prevention and Health, Glostrup University
Hospital, Glostrup, Denmark, 7Department of Integrative Biology, University of California, Berkeley, Berkeley, California, United States of America, 8Department of
Statistics, University of California, Berkeley, Berkeley, California, United States of America, 9 Landspitali, The National University Hospital of Iceland, Department of Clinical
Biochemistry, Reykjavik, Iceland, 10 Icelandic Medical Center (Laeknasetrid) Laboratory in Mjodd (RAM), Reykjavik, Iceland, 11 Faculty of Health and Medical Sciences,
University of Copenhagen, Copenhagen, Denmark, 12 Faculty of Medicine, University of Aalborg, Aalborg, Denmark, 13 Faculty of Health Sciences, University of Southern
Denmark, Odense, Denmark, 14University of Iceland Faculty of Medicine, Reykjavik, Iceland, 15 Faculty of Health Sciences, Aarhus University, Aarhus, Denmark,
16Hagedorn Research Institute, Gentofte, Denmark, 17 Institute of Biomedical Science, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen,
Denmark
Abstract
Genome-wide association studies have mainly relied on common HapMap sequence variations. Recently, sequencing
approaches have allowed analysis of low frequency and rare variants in conjunction with common variants, thereby
improving the search for functional variants and thus the understanding of the underlying biology of human traits and
diseases. Here, we used a large Icelandic whole genome sequence dataset combined with Danish exome sequence data to
gain insight into the genetic architecture of serum levels of vitamin B12 (B12) and folate. Up to 22.9 million sequence variants
were analyzed in combined samples of 45,576 and 37,341 individuals with serum B12 and folate measurements, respectively.
We found six novel loci associating with serum B12 (CD320, TCN2, ABCD4, MMAA, MMACHC) or folate levels (FOLR3) and
confirmed seven loci for these traits (TCN1, FUT6, FUT2, CUBN, CLYBL, MUT, MTHFR). Conditional analyses established that
four loci contain additional independent signals. Interestingly, 13 of the 18 identified variants were coding and 11 of the 13
target genes have known functions related to B12 and folate pathways. Contrary to epidemiological studies we did not find
consistent association of the variants with cardiovascular diseases, cancers or Alzheimer’s disease although some variants
demonstrated pleiotropic effects. Although to some degree impeded by low statistical power for some of these conditions,
these data suggest that sequence variants that contribute to the population diversity in serum B12 or folate levels do not
modify the risk of developing these conditions. Yet, the study demonstrates the value of combining whole genome and
exome sequencing approaches to ascertain the genetic and molecular architectures underlying quantitative trait
associations.
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Introduction
One-carbon metabolism (OCM) is a process whereby folate
transfers one-carbon groups in a range of biological processes
including DNA synthesis, methylation and homocysteine metab-
olism [1,2]. The water-soluble B vitamins, vitamin B12 (B12) and
folate play key roles as enzyme cofactors or substrates in OCM.
Individuals with deficiencies in these vitamins can develop anemia
and, in the case of B12 deficiency, serious neurological problems.
In adults, epidemiological studies have also suggested that
subclinical B12 or folate deficiencies are associated with increased
risk of cardiovascular disease [3,4], different cancers [5,6] and
neurodegenerative disease such as Alzheimer’s disease [7]. Serum
levels of B12 and folate are in addition to nutrition influenced by
several biological processes including absorption, transportation
and cellular uptake, as well as processing of precursors into active
molecules. Heritability, utilizing di- and monozygotic twins, is
estimated to be 59% and 56% for B12 and folate levels,
respectively, indicating that there is a substantial genetic compo-
nent to the population diversity in these physiological variables [8].
Identification of sequence variants that affect circulating levels of
B12 and folate can thus give insights into the interplay of diet,
genetics and human health. Genome-wide association studies
(GWAS) have yielded some sequence variants influencing B12
levels [9–12], but have been less successful in identifying variants
affecting folate levels [10,11]. Thus, genome-wide significant
associations with serum B12 levels have been convincingly reported
for four loci, FUT2, MUT, CUBN and TCN1 in European
populations [9–11] and additional four loci, MS4A3, CLYBL,
FUT6 and 5q32 in a Chinese population [12]. No genome-wide
significant GWAS associations have been reported for serum folate
levels, however, significant association with the MTHFR A222V
variant was demonstrated prior to the GWAS era [13,14] and
suggestive associations have been reported in European popula-
tions for two loci (FIGN and PRICKLE2) [10,11].
The classic GWAS applied commercial chip-based genotyping
and imputation of HapMap variants of which a majority were
common single nucleotide variants (SNVs) with very few rare
variants with minor allele frequency (MAF) ,1% [15,16].
However, the search for the truly associated functional variants
and the targeted gene at each locus has been hindered by the lack
of coverage of the full spectrum of the sequence variation of the
human genome. Recently, focus has turned to the use of next
generation sequencing of whole genomes (WGS) [17], exomes
(WES) [18] or specific targets [19], all contributing to a better
understanding of the spectrum of allelic variations in the human
genome. We expect that attempts to directly cover low frequency
and rare sequence variants through next generation sequencing, in
addition to the common variants, will improve the search for
functional variants and thus the understanding of the underlying
biology of human traits and diseases.
Here we aimed to identify and characterize associations of
SNVs across the allele frequency spectrum with serum levels of B12
and folate by compiling data in up to 45,576 individuals based on
sequencing initiatives in Iceland and Denmark. For the first time
we apply next generation sequence data to identify sequence
variants affecting serum levels of B12 and folate and the present
datasets are the largest utilized to date for the analysis of these
traits.
Results
Heritability of serum B12 and folate levels
We estimated the heritability of B12 and folate serum levels
based on 38,229 and 21,708 Icelandic sibling pairs, respectively.
Our analysis revealed estimates of 27% for B12 and 17% for folate
which are lower than previously reported [8].
Experimental design
To search for sequence variants affecting serum B12 and folate
levels we compiled data from two sequencing initiatives in Iceland
and Denmark. In Iceland, a large population-based resource has
been generated applying WGS and highly accurate imputation of
the sequence information into a large fraction of the population
[20,21]. Utilizing this resource many low frequency and rare
causative sequence variants have recently been discovered that
affect the risk of common diseases [22–26]. In the Danish samples,
WES was used to search for low frequency variation associated
with complex traits [27,28]. The outline of the present study is
depicted in Figure 1. In the Icelandic study sample, 1,176
individuals were whole genome sequenced to an average depth of
.106and 22.9 million SNVs were identified. These variants were
then imputed into 25,960 and 20,717 chip-genotyped Icelanders
with serum B12 and folate measurement, respectively, using highly
accurate long-range phasing based imputation [20]. The Icelandic
genealogical database allowed for further propagation of the
sequence information, applying genealogy based imputation, into
11,323 and 8,196 relatives of the chip-genotyped individuals, for a
total sample size of 37,283 and 28,913, respectively, for the two
phenotypes [25] (Text S1 and Table S1). In the Danish part of the
study whole exomes of 2,000 Danes were sequenced to an average
sequencing depth of 86 [28]. From that effort, 16,192 coding
SNVs with allelic frequency above 1% were selected for Illumina
iSelect genotyping in two Danish population-based cohorts of
8,293 individuals with measurements of serum B12 and 8,428
individuals with measurement of serum folate (Table S2). Of the
16,192 SNVs, 15,994 overlapped with the Icelandic variants.
A generalized form of linear regression was used to test for
association of serum levels of B12 or folate with SNVs, taking into
account relatedness and population stratification within each
sample set, applying the method of genomic control (GC).
Analyses were performed in three steps; sequence variants were
analyzed in the Icelandic and Danish samples separately, then by
combining in a meta-analysis the overlapping sequence variants
identified in both study samples. Loci that associated significantly
with B12 or folate levels from these studies were fine mapped using
the Icelandic WGS data imputed into chip genotyped individuals
and the same data set was used to identify additional signals at
Author Summary
Genome-wide association studies have in recent years
revealed a wealth of common variants associated with
common diseases and phenotypes. We took advantage of
the advances in sequencing technologies to study the
association of low frequency and rare variants in conjunc-
tion with common variants with serum levels of vitamin
B12 (B12) and folate in Icelanders and Danes. We found 18
independent signals in 13 loci associated with serum B12 or
folate levels. Interestingly, 13 of the 18 identified variants
are coding and 11 of the 13 target genes have known
functions related to B12 and folate pathways. These data
indicate that the target genes at all of the loci have been
identified. Epidemiological studies have shown a relation-
ship between serum B12 and folate levels and the risk of
cardiovascular diseases, cancers, and Alzheimer’s disease.
We investigated association between the identified vari-
ants and these diseases but did not find consistent
association.
Genetics of B12 and Folate Mapped by Sequencing
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each of these loci trough conditional analysis. Finally, the full
Icelandic data of 22.9 million SNVs were used in GWAS to
identify additional loci represented by non-coding variants or rare
coding signals not genotyped in the Danish design. Genome-wide
significance (GWS) level in the study was set at P,2.261029,
based on Bonferroni correction for the 22.9 million SNVs
(Figure 1).
Discovery analyses for serum B12 and folate
In the separate and combined analyses of SNVs with serum B12
and serum folate levels in the Icelandic and Danish data, a total of
13 genetic loci were found to associate at GWS, P,2.261029
(Table 1 and 2, Figure S1 and S2). Of the 11 loci associated with
serum B12, five (CD320, TCN2, ABCD4, MMAA and MMACHC)
were novel and six were previously reported either in populations
of European or East-Asian ancestry [9–12] (Table 1). Association
analyses with serum folate yielded one novel locus (FOLR3) and
confirmed the reported MTHFR locus (Table 2).
Since only coding variants were in the combined analysis we
used the Icelandic WGS-based data to screen for stronger non-
coding signals at the loci identified in meta-analysis of coding
variants. Interestingly, the strongest signal at 10 of the 11 B12-
associated loci in the Icelandic data corresponded to missense
(n=9) or nonsense (n=1) mutations with only the FUT6 locus
having a stronger non-coding signal (rs708686) than the missense
P124S mutation (Table S3). As only SNVs had been called from
the WGS data and imputed into the Icelandic samples we
reassessed each of the 13 B12 and folate loci with INDEL data
called using the GATK algorithm (http://www.broadinstitute.
org/gatk/). None of the INDELs detected at the 11 B12 loci
associated more strongly than the lead SNVs. However,
when reassessing each of the two folate-associated loci we
detected a two nucleotide insertion (rs139130389, NM_000804:
exon3:c.318_319insTA) encoding a common (MAF 10.0%)
frameshift mutation in exon 3 of FOLR3, that associated more
strongly with folate levels than the intronic SNV rs652197
identified in the initial scan (rs139130389: P=2.45610212;
effect = 0.087 SD, Table 2). The insertion and rs652197 are in
linkage disequilibrium (LD) in the Icelandic sequencing data
(r2 = 0.51). Upon further inspection, we found that the ancestral
sequence contained the insertion indicating the occurrence of a
two base deletion in humans. The deletion with an allelic
frequency of 90% in Iceland creates a premature stop codon at
amino acid position 107 compared to the full-length protein
consisting of 245 amino acids. Coding variants are thus lead signal
of both folate loci (FOLR3 and MTHFR).
The lead SNVs included both rare, low frequency and common
variants with MAFs ranging from 0.2% to 48% (Table 1 and 2).
Of the six novel loci, four contained a lead variant with MAF
below 6% with the rare missense rs12272669 variant (MAF
0.22%) in MMACHC that associates with B12 found in the
Icelandic data being at the extreme (Table 1). This variant has
been observed in other populations than the Icelandic, albeit at
much lower frequency (MAF 0.02%) (Exome Variant Server,
http://evs.gs.washington.edu/EVS/). For TCN1 and FUT6 pre-
viously reported to associate with serum B12 levels we confirmed
the association, yet with different SNVs than reported. At the
TCN1 locus the strongest associated SNV in the Icelandic data was
rs34324219 (Table 1) encoding a D301Y missense mutation,
whereas the reported [10,11] and correlated (r2 = 0.28) non-coding
rs526934 was more weakly associated (Table S4). At the FUT6
locus, the P124S missense mutation (rs778805) identified in the
combined analysis of Icelandic and Danish data associated more
strongly (Table 1) than the previously reported promoter
rs3760776 variant (Table S4). For the remaining four reported
B12-associated loci, MUT, FUT2, CUBN and CLYBL, we
Figure 1. Schematic overview of the study.
doi:10.1371/journal.pgen.1003530.g001
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confirmed the association signal [9–11] (Table 1). At the MTHFR
locus the strongest folate association was for the major allele of the
common A222V (rs1801133) for which previous association with
serum folate has been reported [10,13,14] (Table 2).
For the two loci reported to associate with B12 levels in
individuals of East-Asian ancestry (MSRA and 5q32) the variant
was either not present in the Icelandic data or at very low
frequency (Table S4) whereas the reported non-coding folate
signals at FIGN and PRICKLE2 loci did not replicate in the
Icelandic folate data (Table S5).
At a less stringent significance level of P,161026 we found
three additional loci, CPS1, SPACA1 and ZBTB10 with suggestive
associations with serum B12 levels (Table S6) while suggestive
association with folate levels at P,161026 was found for eight
additional loci (Table S7).
Analyses conditional on the identified associated
sequence variants
For the 13 loci associated with serum B12 or folate levels we
performed stepwise conditional analyses to search for secondary
signals applying Icelandic WGS data imputed into the 25,960 and
20,717 chip-genotyped Icelanders with serum B12 and folate
information. We detected additional signals at five loci, CUBN,
TCN1, TCN2, FUT6 and MTHFR (Figure 2). For the serum B12-
associated loci, secondary independent association signals at
P,561028 were detected at three, CUBN, TCN1 and TCN2
(Figure 2, Table 3, Table S8), while the secondary independent
signal at FUT6 (observed for the reported B12-associated
rs3760776 upstream of FUT6 [12]) did not reach the threshold
of significance (P=4.461026). The secondary signal at the CUBN
locus was shown for a group of correlated markers represented by
rs56077122 (located in an intron of the neighboring TRDMT1)
(Figure 2). In TCN1 two additional independent signals at
P,561028 for serum B12 were found including a missense variant
(R35H) and an intergenic variant whereas one secondary signal in
the TCN2 locus, represented by rs5753231, was located immedi-
ately 59 to TCN2 (Figure 2, Table 3). In the folate-associated loci, a
secondary independent signal was found at the MTHFR locus
represented by rs17421511 located in intron 4 of the MTHFR
gene (Figure 2, Table 3). In contrast to the lead SNVs a large
fraction of the secondary B12 or folate signals were non-coding.
Of the identified variants (lead and secondary) the fraction of
variance in serum B12 or folate levels explained is estimated to be
6.3% for B12 and 1.0% for folate (Text S1).
Mapping effects of associated sequence variants on gene
expression
To determine whether any of the lead or secondary association
signals at the B12 or folate loci affect the expression of the target
gene we analyzed genome-wide expression QTL (eQTL) data
from white blood cells (n=1,001) and adipose tissue (n=673) from
Icelanders with information on 22.9 million SNVs [29]. Of the
lead and secondary B12 or folate signals that are coding (Tables 1–
3) two showed strong association with the expression of the target
gene; the R532H missense variant in MUT (P=9.1610259 in
white blood cells and P=2.5610216 in adipose tissue) and the
frameshift INDEL in FOLR3 (P=7.16102110 in white blood cells
and P=2.5610262 in adipose tissue; Table S9). Of all the cis
variants at the MUT locus the R532H missense mutation had by
far the strongest effect on MUT expression indicating that this
effect is not mediated by a non-coding regulatory variant in LD
with the R532H mutation. The large effect of the frameshift
mutation on FOLR3 expression is likely caused by nonsense-
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mediated decay of transcripts containing the premature termina-
tion mutation [30]. A similar effect was not seen for the nonsense
mutation in the CLYBL gene which can likely be explained by the
closeness of the mutation to the N-terminal of the CLYBL protein
(amino acid 259 of 340) (Table S9). Of the non-coding lead or
secondary B12 or folate signals a statistically significant effect on
Figure 2. Regional plots illustrating conditional analyses of loci with more than one independent association signal for serum B12
(CUBN, TCN1 and TCN2) or serum folate (MTHFR). Genotyped and imputed SNVs passing quality control measures in the Icelandic data are
plotted with their P-values (as2log10 values) as a function of genomic position (NCBI Build 36). Only SNVs with P,1025 in at least one of the models
are shown. The analyses were performed in 25,960 and 20,717 chip-genotyped Icelanders for B12 and folate, respectively. Data points illustrated by
open circles represent unconditional analyses (M0); blue dots are results of analyses conditional on the most significant SNV in M0 (M1) and orange
dots are results of analyses conditional on most significant SNVs in M0 and M1. Estimated recombination rates (HapMap CEU) are plotted to reflect
the local LD structure. Gene annotations were obtained from RefGene.
doi:10.1371/journal.pgen.1003530.g002
Table 3. Novel secondary association signals at the serum B12 or serum folate loci that associate at P,5610
28.
SNV # SNV name Chr.
Position
(build 36) Gene Annotation
Alleles
(effect/other) EAF Effect P
LD with
SNV #1
(r2)
LD with
SNV #2
(r2)
CUBN region (B12)
1 rs1801222 10 17,196,157 CUBN F253S G/A 0.593 0.11 2.3610242
2 rs56077122 10 17,247,021 TRDMT1 intronic A/C 0.335 0.087 4.8610221 0.033
TCN1 region (B12)
1 rs34324219 11 59,379,954 TCN1 D301Y C/A 0.889 0.21 9.8610262
2 rs34528912 11 59,388,111 TCN1 R35H T/C 0.0361 0.17 2.1610215 0.0040
3 rs117456053 11 59,373,407 Near TCN1 Intergenic G/A 0.976 0.16 1.961029 0.0035 0.0011
TCN2 region (B12)
1 rs1131603 22 29,348,975 TCN2 L376S C/T 0.055 0.17 1.1610221
2 rs5753231 22 29,333,069 TCN2 59 C/T 0.79 0.064 7.5610210 0.014
MTHFR region (folate)
1 rs1801133 1 11,778,965 MTHFR A222V G/A 0.668 0.10 3.4610227
2 rs17421511 1 11,780,375 MTHFR Intronic G/A 0.827 0.098 1.8610215 0.11
Conditional analyses were performed using imputed sequence data from chip-genotyped Icelanders with information on serum B12 or folate levels. Results for SNV #1
(lead SNVs) at each loci are unconditional on other SNVs. Analysis of SNV #2 is conditional on SNV #1 and SNV #3 is conditional on SNV #1 and #2. The LD between
the SNVs at each locus was estimated from the sequence information of the 1,179 whole genome sequenced Icelanders.
doi:10.1371/journal.pgen.1003530.t003
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expression was only seen for the TCN2 promoter variant, however,
other markers in the region, that had no effect on serum B12 levels
associated more strongly with TCN2 expression. Although lack of
appropriate tissue to evaluate the effect of the B12 and folate
mutations on expression cannot be excluded, these data suggest
that except for the MUT gene the effects of both the coding and
non-coding mutations are unlikely to be through expression.
Association of identified sequence variants with other
traits linked to B12 and folate levels
Rare mutations in some of the B12 genes described here i.e.
MMACHC, MMAA, MUT, CD320, TCN2 and CUBN have been
described in connection with rare conditions of methylmalonic
aciduria and megaloblastic anemia that all relate to defects in B12
metabolism (OMIM database, http://www.ncbi.nlm.nih.gov/
omim/). In addition, epidemiological studies have suggested a
link between reduced B12 and folate levels and the risk of common
conditions such as cardiovascular diseases [3,4], cancers [5,6] and
neurodegenerative disorders [7]. To evaluate the effect of the B12
or folate variants on these conditions we analyzed the association
with coronary artery disease (CAD), stroke, colon cancer, prostate
cancer and Alzheimer’s disease in data obtained from deCODE’s
phenotype database. As outlined in Table S10, variants associated
with serum B12 or folate levels did not consistently affect the risk of
the diseases tested; the B12 or folate increasing allele for some
variants was weakly protective and for others weakly at risk, and
only two loci (CUBN associated with CAD and MTHFR with
stroke) were statistically significant (P,0.0018) but with opposite
effects on these diseases. B12 or folate deficiencies can lead to
increased serum homocysteine [2], yet of all the B12 or folate loci
tested only two associated significantly with homocysteine levels,
with the B12 or folate increasing allele decreasing the homocyteine
levels as expected (Table S10). These loci were the folate-
associated MTHFR variant previously reported to associate with
homocysteine [10,31,32] and the B12-associated variant at the
MUT locus. Neither of these loci associated with cardiovascular
disease or Alzheimer’s disease, despite increased homocysteine has
been suggested to increase the risk of these diseases. Deficiency of
B12 or folate is associated with megaloblastic anemia characterized
by the presence of abnormally large red blood cells, increased
mean corpuscular volume (MCV) and increased mean corpuscular
hemoglobin (MCH). None of the identified variants associated
significantly with MCV and MCH (Table S10). We also tested the
recessive model for the B12 or folate variants in relation to these
conditions, but did not detect any new associations. Inconsistency
in the direction of the effect of each of the variants on these
conditions (increased or decreased risk) (Table S10) indicates that
for a given condition the combined effect of all the variants would
be consistent with lack of association. The absence of observed
directional consistent effects of the B12 and folate variants on the
phenotypes tested suggest that sequence variants that contribute to
the population diversity in serum B12 or folate levels do not modify
the risk of developing these conditions, likely reflecting that B12
and folate levels have weak effects on these conditions. However,
we recognize that for some of the conditions analyzed sample sizes
are too small to detect weak effects, calling for cautious
interpretation.
Evaluation of pleiotropic effects of the identified variants
One of the B12-associated loci, FUT2, has previously been
associated with reduction in liver enzymes including alkaline
phosphatase (ALP) [33] and cholesterol levels [34], increased risk
of Crohn’s disease [35,36], psoriasis [37], retinal vascular caliber
[38] and type 1 diabetes [39] and protection against Norovirus
infection [40]. These associations can be explained by the function
of FUT2 in cell surface glycobiology as determinant of the Lewis
antigen blood group. To evaluate pleiotropic effects of the
identified B12 and folate variants, we screened the deCODE
phenotype database, which contains information on the majority
of common diseases and their associated risk factors (n=400),
applying both multiplicative and recessive genetic models
(P=3.561026 after Bonferroni correction). We found that the
FUT2 variant associated strongly with serum levels of ALP
(P=1.1610273) and also with psoriasis (P=4.361023) as previ-
ously reported. We also detected a strong association with serum
levels of cancer antigen 19-9 (P=1.16102146), lipase
(P=2.2610224) and suggestive association with bone mineral
density (BMD) (P=1.361025) with the B12-increasing allele
decreasing ALP levels, increasing the serum levels of the cancer
antigen 19-9 and lipase and increasing the risk of developing low
BMD (osteoporosis) (Table S11). An increase in serum lipase is
associated with Crohn’s disease [41], but the causal link is unclear.
The increased risk for low BMD observed for the FUT2 variant
may be secondary to reduced ALP activity that might be a
reflection of reduced bone remodeling. When applying the
recessive model to the B12 and folate variants we found suggestive
associations of the FUT6 variant with abdominal aortic aneurysm
(AAA) and of the folate-associated variant in MTHFR with
thoracic aortic aneurysm (TA). In both cases the effect of the B12-
or folate-increasing allele was protective (Table S11). These
associations could be mediated through the effect of these variants
on B12 and folate levels as reduced levels of B12 and folate have
been linked to the development of aortic aneurysm [42].
Discussion
Here we performed association analyses of up to 22.9 million
SNVs, identified through WGS and WES, in up to 45,576
individuals to identify and characterize genetic variation influenc-
ing population diversity in serum levels of B12 and folate. We
discovered five novel loci that associate with serum B12 levels and
one novel locus for folate levels and replicated the six reported B12
loci and one folate locus. In addition, we identified five novel
secondary independent signals at both the new and previously
reported loci. The fraction of variance in serum B12 or folate levels
explained by the identified variants is estimated to be 6.3% for B12
and 1.0% for folate (Text S1). Of the identified SNVs, both
common and rare, we find that a large fraction (13 of 18) is
represented by coding variants which is an unusually high fraction
of coding variants compared to previous GWAS for other traits.
Furthermore, of the 13 loci that associate with serum B12 and
folate levels the genes at 11 of them can be directly linked to the
current understanding of B12 and folate metabolism such as
absorption, transport or enzymatic processes and one (FUT6) has
potential links with these processes (Figure 3). Only CLYBL has a
function that cannot be directly related to these pathways.
Specifically, eight loci are involved in transporting B12 and folate
between different tissues, four of them TCN1, FUT2, FUT6 and
TCN2 as co-factors or regulators of co-factors necessary for the
transport and the other four, CUBN, CD320, ABCD4 [43] and
FOLR3 as membrane transporters actively facilitating membrane
crossing. MUT and MTHFR catalyze enzymatic reactions in the
OCM where MMACHC and MMAA are involved in co-enzymatic
processes (Figure 3). Moreover, we note that of the 13 genes, two
(TCN2 and CD320) are known and two (MUT and MMAA) are
suggested to interact in vivo [44] (Figure 3). Together with the high
fraction of coding mutations these data indicate that the target
genes at all of the loci have been identified.
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By screening the deCODE database for pleiotropic effects of
the B12 and folate variants we replicated some of the previous
associations of the FUT2 gene and detected novel suggestive
association with increased risk of osteoporosis (low BMD)
potentially mediated through diminished bone remodeling as a
consequence of reduced ALP activity. We also detected suggestive
associations of the FUT6 and the MTHFR variants with AAA and
TA, respectively. However, we did not demonstrate association of
any of the variants with the cardiovascular diseases, CAD and
stroke, colorectal cancer, prostate cancer or Alzheimer’s disease
and only two of the variants associated with homocysteine levels.
Although to some degree impeded by low statistical power for
some of these conditions, these data suggest that sequence
variants that contribute to the population diversity in serum B12
or folate levels do not modify the risk of developing these
conditions.
Figure 3. Genes that associate with serum B12 and folate levels are in pathways affecting their metabolism. Genes previously identified
to harbor variants regulating serum levels of B12 are shown in green. In blue are novel genes identified in the present study. In red, genes containing
variants previously suggested to associate with serum folate and in purple are novel genes for serum folate. B12: vitamin B12; HC: Heptocorrin (TCN1);
IF: Intrinsic factor; R-A-P: Receptor-Associated-Protein; CUBN: cubilin (intrinsic factor-cobalamin receptor); TCII: Transcobalamin II (TCN2); TCII-R:
Transcobalamin II receptor (CD320); MMACHC: methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria; MMAA: methylmalonic
aciduria (cobalamin deficiency) cblA type; ABDC4: ATP-binding cassette, sub-family D (ALD), member 4; LMBD1: LMBR1 domain containing 1; FOLR1–
3: folate receptors 1–3; Ado-B12: Adenosyl-cobalamin; Me-B12: Methyl-cobalamin; Me-mal-CoA: Methyl-malonyl-CoenzymeA; Suc-CoA: Succinyl-
CoenzymeA; MUT: methylmalonyl-CoA mutase; H. pylori: Helicobacter pylori; DHFR: Dihydrofolate reductase; MS: methionin synthase; THF:
Tetrahydrofolate; 5,10-MTHF: 5,10-Methyl-tetrahydrofolate; Hcy: Homocysteine MTHFR: 5-methyl-tetrahydrafolate reductase.
doi:10.1371/journal.pgen.1003530.g003
Genetics of B12 and Folate Mapped by Sequencing
PLOS Genetics | www.plosgenetics.org 8 June 2013 | Volume 9 | Issue 6 | e1003530
Materials and Methods
Ethics statement
All participants gave written informed consent. The studies were
conducted in accordance with the Declaration of Helsinki II and
were approved by the local Ethical Committees (approval
numbers Denmark: H-3-2012-155, KA 98155 and KA-
20060011, DeCode 08-105-V3-S1 (issued 30.08.2011) ref.
VSNb2008060006/03.1).
Study participants in Iceland
For the Icelandic samples, serum B12 and folate levels were
assessed in blood samples from Icelanders at the Landspitali
University Hospital Laboratory or at the Icelandic Medical Center
(Laeknasetrid) Laboratory in Mjodd (RAM), between the years
1990 and 2011. B12 and folate levels were normalized to a
standard normal distribution using quantile normalization and
then adjusted for sex, year of birth and age at measurement. For
individuals for which more than one measurement was available
we used the average of the normalized value.
Study participants in Denmark
The Danish data were generated in two population-based study
samples recruited in Copenhagen. The Inter99 cohort is a
randomized, non-pharmacological intervention study for the
prevention of ischaemic heart disease, conducted on 6,784
randomly ascertained participants aged 30 to 60 years at the
Research Centre for Prevention and Health in Glostrup, Denmark
[45] (ClinicalTrials.gov: NCT00289237). Detailed characteristics
of Inter99 have been published previously [45–47]. The Inter99
cohort included 5,481 and 5,624 individuals with genotypes and
measurement of serum B12 and folate, respectively. Health2006 is
a population-based epidemiological study of general health,
diabetes and cardiovascular disease of 3,471 individuals aged
18–74 years [48]. Health2006 was also conducted at the Research
Centre for Prevention and Health in Glostrup, Denmark. The
Health2006 cohort included 2,812 and 2,804 individuals with
valid genotypes and measurement of serum B12 and folate,
respectively. In Inter99 serum B12 and folate were measured by a
competitive chemiluminescent enzyme immunoassay (Immulite
2000 System; Siemens Medical Solutions Diagnostics, Los
Angeles, CA, USA) as previously reported [14]. In Health2006,
serum B12 and folate were measured by chemiluminescent
immunoassay (Dimension Vista platform, Siemens Healthcare
Diagnostics GmbH, Eschborn, Germany).
Genotype data generation
In the Icelandic part, SNVs were identified through the
Icelandic WGS project. A total of 1,176 Icelanders were selected
for sequencing based on having various neoplasic, cardiovascular
and psychiatric conditions. All of the individuals were sequenced
to a depth of at least 106. The generation of genotypic data in
Iceland is detailed in earlier reports [23] and in Text S1, and
consisted of the following steps: SNV calling and genotyping in
WGS, long range phasing, genotype imputation and in silico
genotyping.
In the Danish part of the study 16,192 SNVs for genotyping
were selected from a WES study of 2,000 individuals [28]. In
brief, exon capture and Illumina sequencing to a depth of 86
were performed in 2,000 Danes by methods previously described
[27]. The exome was captured by a NimbleGen 2.1M HD array
with a target region of 34.1 Mb including 18,954 genes defined
by CCDS (Consensus Coding Sequence database). The average
number of reads sequenced for each individual was 22.3 million
with most reads being 30 to 80 bases long. After alignment to the
human reference genome (assembly hg18, NCBI build 36.3) and
stringent quality assurance, including uniqueness of genomic
mapping and Q-score .20, the median coverage per individual
was 91% of the target region and had an average depth of 86
(96% coverage and 116 depth before filtering). After applying
quality criteria 70,182 SNVs with an estimated MAF above 1%
based on the reads using maximum likelihood were identified
[49]. The details of the WES have been described previously
[28]. 20,005 SNVs were, as part of a published study, selected
from the exome sequencing for genotyping in 16,888 samples by
a custom-designed Illumina iSelect array. First, 18,358 SNVs
annotated to the most likely deleterious categories (179 nonsense,
15,789 nonsynonymous, 219 located in splice sites and 2,171 in
untranslated regions) were prioritized. Second, 1,048 SNVs
nominally associated with type 2 diabetes (P,0.05) in a
sequencing-based association study were selected. Finally, we
selected 599 synonymous variants in 192 loci previously
associated with common metabolic traits at GWS. Genotype
data was obtained for 18,744 SNVs. Quality control of samples
included removing closely related individuals, individuals with an
extreme inbreeding coefficient, individuals with a low call rate,
individuals with a mislabeled sex and individuals with a high
discordance rate to previously genotyped SNVs. 15,989 individ-
uals passed all quality control criteria. The SNVs were filtered
based on their MAF (.0.5%), genotype call rate (.95%), Hardy-
Weinberg equilibrium (P.1027) or cross-hybridization with the
X-chromosome. 16,192 SNVs passed all filters [28]. Genotyping
of FOLR3 rs652197 in Danish samples was done by KASPar SNP
Genotyping System (KBioscience, Hoddesdon, UK).
Statistical analyses
Icelandic analyses and quantitative trait association
testing. A generalized form of linear regression was used to
test for association of serum B12 and folate with SNVs. Let y be the
vector of quantitative measurements, and let g be the vector of
expected allele counts for the SNV being tested. We assume the
quantitative measurements follow a normal distribution with a
mean that depends linearly on the expected allele at the SNV and
a variance covariance matrix proportional to the kinship matrix:
y*N(azbg,2s2W),
where
Wij~
1
2
,i~j
2rkij,i=j
(
is based on the kinship between individuals as estimated from the
Icelandic genealogical database (kij) and estimate of the
heritability of the trait (r). It is not computationally feasible to
use this full model and we therefore split the individuals with in
silico genotypes and serum B12 and folate measurements into
smaller clusters. Here we chose to restrict the cluster size to at most
300 individuals.
The maximum likelihood estimates for the parameters a, b, and
s2 involve inverting the kinship matrix. If there are n individuals in
the cluster, then this inversion requires O(n3) calculations, but
since these calculations only need to be performed once the
computational cost of doing a GWAS will only be O(n2)
calculations; the cost of calculating the maximum likelihood
estimates if the kinship matrix has already been inverted.
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Multivariate regression and conditional analyses. For
the multivariate regression analysis we only used Icelandic
individuals which have been genotyped using the Illumina chip-
genotyping platform. The multivariate linear regression analysis
was performed conditioning for a given marker by adjusting for
the estimated allele count based on imputation of this marker. The
GC correction factor was the same as used for the unadjusted
association analysis. A forward selection multiple logistic regres-
sion model was used to further define the extent of the genetic
association. Briefly, all imputed SNVs located within an interval
around the lead SNVs were tested for possible incorporation into a
multiple regression model. In a stepwise fashion, a SNV was added
to the model if it had the smallest P-value among all SNVs not yet
included in the model and if it had a P,561028. In the last step
none of the SNVs remained significant at this threshold.
Association analyses of serum B12 and folate in Danish
samples. Association analysis of each SNV in the Danish data
was performed using linear regression assuming an additive model.
Principal component analysis was performed using the covariance
matrix and the first principal component and sex were included in
the model as covariates. All quantitative traits were quantile
normalized to a normal distribution prior to analysis. Association
analyses were done using PLINK software (version 1.07, http://
pngu.mgh.harvard.edu/purcell/plink/). All P-values were correct-
ed by GC. Inflation factors (l) were at acceptable levels: B12:
Inter99: 1.027, Health2006: 1.014 and folate: Inter99: 1.024,
Health2006: 1.010.
Meta-analyses. For all SNVs with data from more than one
study sample (Icelandic, Inter99 and/or Health2006) we per-
formed meta-analyses of summary association data where we
estimated the combined effect in a fixed-effects meta-analysis using
the METAL software (http://www.sph.umich.edu/csg/abecasis/
Metal/) [50]. An overall z-statistic relative to each reference allele
was estimated based on P-value and direction of effect adjusted for
the number of individuals in each sample.
Supporting Information
Figure S1 Regional plots of the 11 loci associated with serum
B12. Genotyped and imputed SNVs passing quality control
measures are plotted with their meta-analysis P-values (as
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D, Gao Y, Tao S, Yang X, et al. (2012) Genome-wide association
study identifies novel loci associated with serum level of vitamin
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Genome-wide significant predictors of metabolites in the one-
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signals with P,561028. Conditional analyses were performed
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Table S9 Cis-effect of the B12 and folate SNVs on the expression
of the target gene in white blood cells and adipose tissue.
Correlation between SNVs that associate with increased B12 or
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Table S10 Association results for B12 and folate associated
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size and effect allele frequency from the Icelandic population.
Associations at P,0.001 are shown in bold. EAF, effect allele
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Table S11 Association results for the B12 and folate variants with
diseases and traits in deCODE database. Shown are the strongest
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(PDF)
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